glp 1 agonist tirzepatide Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats Beyond GLP-1: New 5-In-1 Compound

Unlike classical type 2 diabetes marked by insulin resistance, this phenotype, estimated to affect 25 million people in LMICs, is characterized by severe pancreatic -cell dysfunction with substantial deficits in insulin secretion, yet insulin sensitivity is preserved, and autoimmunity or ketoacidosis are absent [144]

Caplan took the time to listen to me and after meeting with her I am feeling more hopeful

The FDA is in a public comment period - closing June 29, 2026 - on a proposal to formally exclude semaglutide and tirzepatide from the 503B Bulk Drug Substances List, a move that would permanently close large-scale compounding pathways for these active ingredients even in a future shortage

By mimicking the action of GLP-1, Semaglutide not only prompts the pancreas to produce insulin but also inhibits the release of glucagon, a hormone that raises blood sugar levels

GLP-1 receptor agonists (GLP-1 RA) medications can reduce the number of deaths, amputations and hospitalisations among patients with peripheral arterial disease (PAD) and type 2 diabetes, according to new, independent research published in the Journal of the American Heart Association ( JAHA )

A balanced diet, regular physical activity, and behavioral therapy can enhance the effects of the medication and help maintain weight loss long-term